NCT06019741View on ClinicalTrials.gov

Rivaroxaban Post Coronary Bypass Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

May 1, 2022

Study Completion Date

July 20, 2022

Conditions
Post Coronary Bypass Surgery Patients
Interventions
DRUG

Rivaroxaban and aspirin 80

rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery

DRUG

Aspirin 80

aspirin 80 mg orally post coronary bypass surgery

Trial Locations (1)

55318

Professor Kojuri Cardiology Clinic, Shiraz

All Listed Sponsors
lead

Shiraz University of Medical Sciences

OTHER

NCT06019741 - Rivaroxaban Post Coronary Bypass Surgery | Biotech Hunter | Biotech Hunter